Arcutis Biotherapeutics Inc (ARQT) financials
Arcutis Biotherapeutics revenue and earnings by year
Arcutis Biotherapeutics's revenue was $376 million in the fiscal year to December 31, 2025, up 91.3% from the year before. Net income was -$16.1 million, -4.3% of revenue. Since the fiscal year to December 31, 2022, revenue has grown 367.1% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 4 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 376 | 197 | 60 | 4 |
| Revenue growth | 91.3% | 229.7% | 1517.1% | — |
| Gross profit | 339 | 177 | 55 | 3 |
| Gross margin | 90.2% | 90.3% | 91.6% | 79.5% |
| Operating income | -12 | -128 | -241 | -302 |
| Operating margin | -3.3% | -65.3% | -404.5% | -8183.0% |
| Net income | -16 | -140 | -262 | -311 |
| Net margin | -4.3% | -71.3% | -439.8% | -8449.8% |
| Diluted EPS | -$0.13 | -$1.16 | -$3.78 | -$5.66 |
| Free cash flow | -6 | -112 | -247 | -258 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ARQT in Markets.
How Arcutis Biotherapeutics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| ZORYVE Foam | $67.4M | 51.9% |
| ZORYVE Cream0 3 | $35.3M | 27.2% |
| ZORYVE Cream0 15 | $24.2M | 18.7% |
| ZORYVE Cream0 05 | $2.93M | 2.3% |
See also: ARQT valuation and P/E history · ARQT returns
No forecast, no recommendation. This page describes Arcutis Biotherapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.